Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial

We recently showed that the addition of fractionated doses of gemtuzumab ozogamicin (GO) to standard chemotherapy improves clinical outcome of acute myeloid leukemia (AML) patients. In the present study, we performed mutational analysis of 11 genes (FLT3, NPM1, CEBPA, MLL, WT1, IDH1/2, RUNX1, ASXL1,...

Descripción completa

Detalles Bibliográficos
Autores principales: Renneville, Aline, Abdelali, Raouf Ben, Chevret, Sylvie, Nibourel, Olivier, Cheok, Meyling, Pautas, Cécile, Duléry, Rémy, Boyer, Thomas, Cayuela, Jean-Michel, Hayette, Sandrine, Raffoux, Emmanuel, Farhat, Hassan, Boissel, Nicolas, Terre, Christine, Dombret, Hervé, Castaigne, Sylvie, Preudhomme, Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011594/
https://www.ncbi.nlm.nih.gov/pubmed/24659740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011594/
https://www.ncbi.nlm.nih.gov/pubmed/24659740

Ejemplares similares